Rebecca Lord
Adult Health · Richmond, VANPI 1215227145
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 363 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 363 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$1K
- Lilly USA, LLC$862
- Abbott$731
- Amgen$602
- Insulet Corporation$400
- plus $4K from 36 others
What the payments were for
- Food & beverage$8,36999%
- Education$1021%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 57 | $1,196 |
| AstraZeneca | 55 | $1,055 |
| Lilly USA, LLC | 36 | $862 |
| Abbott | 38 | $731 |
| Amgen | 16 | $602 |
| Insulet Corporation | 11 | $400 |
| Dexcom, Inc. | 11 | $385 |
| Zealand Pharma US, Inc. | 9 | $319 |
| AbbVie | 13 | $288 |
| Xeris Pharmaceuticals, Inc. | 10 | $200 |
| Tandem Diabetes Care, Inc. | 7 | $193 |
| Medtronic | 10 | $185 |
| Sanofi-aventis U.S. LLC | 8 | $185 |
| Astellas Pharma US Inc | 4 | $153 |
| Sequel Med Tech, LLC | 1 | $150 |
| Clarus Therapeutics Inc. | 8 | $145 |
| Antares Pharma, Inc. | 7 | $136 |
| Lifescan, Inc. | 6 | $133 |
| Ascendis Pharma Endocrinology Inc | 2 | $120 |
| Boehringer Ingelheim | 7 | $119 |
| Amneal Pharmaceuticals LLC | 7 | $118 |
| Mannkind Corporation | 5 | $117 |
| Tolmar, Inc. | 5 | $90 |
| Intuity Medical Inc | 3 | $77 |
| Radius Health, Inc. | 2 | $59 |
| Eisai Inc. | 2 | $54 |
| Cequr Corporation | 3 | $51 |
| Amarin Pharma, Inc. | 2 | $41 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Bayer | 2 | $38 |
| Merck | 2 | $32 |
| Esperion Therapeutics, Inc. | 2 | $26 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Halozyme Inc | 1 | $21 |
| Recordati_rare_diseases_inc. | 1 | $21 |
| Novartis | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Pfizer | 1 | $16 |
| IBSA Pharma Inc. | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Acella Pharmaceuticals, LLC | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$243
- DEXCOM G6 TRANSMITTER$234
- Repatha$226
- TWIIST$150
- Wegovy$124
- EVENITY$115
- V-GO DISPOSABLE INSULIN DELIVERY$112
- FREESTYLE LIBRE 3$111
- RYBELSUS$111
- FreeStyle Libre 2$109
How this compares
$8,470 in reported general payments places this provider in the 95th percentile of 368 adult health providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 201 | $264,961 |
| OzempicSemaglutide | 145 | $184,921 |
| JardianceEmpagliflozin | 62 | $73,181 |
| Xigduo XrDapaglifloz Propaned/Metformin | 56 | $52,687 |
| TrulicityDulaglutide | 40 | $50,548 |
| FarxigaDapagliflozin Propanediol | 48 | $48,513 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 32 | $36,214 |
| Tresiba Flextouch U-100Insulin Degludec | 60 | $34,967 |
| JanuviaSitagliptin Phosphate | 31 | $30,379 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $20,594 |
| FiaspInsulin Aspart (Niacinamide) | 15 | $18,481 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $16,829 |
| HumalogInsulin Lispro | 29 | $16,258 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 18 | $11,954 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 11 | $11,553 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $862 | $333,938293 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $1,196 | $206,350176 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $119 | $127,911123 claims |
| AstraZenecaFarxiga | $1,055 | $48,51348 claims |
| MerckJanuvia, Janumet Xr | $32 | $39,79044 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $118 | $4,901256 claims |
| AbbVieSynthroid | $288 | $3,80443 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 368 adult health providers in Virginia.
Other adult health in Richmond
- Veronica HughesRichmond$12K
- Shawna BloweRichmond$7K
- Michele EvansRichmond$7K
- Andrea FunaiRichmond$7K
- Mona BrennerRichmond$5K
- Rachel VenableRichmond$5K
- Ana WileyRichmond$4K
- Christine KesslerFort Belvoir$107K
- Denise BruenCharlottesville$45K
- Theresa Harrington StukusFairfax$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.